SCHEMBL404807

SCHEMBL404807

CCOC(=O)c1sc(Cl)nc1-c1ncnn1CC1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
SLC34A1 Q06495 3/20 0.39
ALDH1A1 P00352 5/20 0.36
HSD17B10 Q99714 2/20 0.36
GAA P10253 2/20 0.36
TSHR P16473 2/20 0.36
HTT P42858 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
CDC7 O00311 2/20 0.36
DBF4 Q9UBU7 2/20 0.36
MAPT P10636 3/20 0.35
CNR2 P34972 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL403810 0.87 ALDH1A1 (0.51) LMNASLC34A1ALDH1A1HSD17B10GAA
SCHEMBL401914 0.87 ALDH1A1 (0.40) ALDH1A1HSD17B10PDE4APDE4BPDE4C
SCHEMBL404775 0.82 FBP1 (0.39) ALDH1A1HSD17B10GAACDC7DBF4
SCHEMBL404165 0.81 ALDH1A1 (0.41) ALDH1A1HSD17B10CDC7DBF4MAPT
SCHEMBL401694 0.73 ALDH1A1 (0.57) LMNAALDH1A1HSD17B10GAATSHR
SCHEMBL404166 0.71 NPC1 (0.46) LMNAALDH1A1HSD17B10CDC7DBF4
SCHEMBL1505433 0.70 LMNA (0.48) LMNAALDH1A1HSD17B10CDC7DBF4
SCHEMBL3403886 0.70 CDC7 (0.43) LMNAALDH1A1HSD17B10GAACDC7
SCHEMBL404580 0.69 ALDH1A1 (0.52) LMNAALDH1A1HSD17B10GAACDC7
SCHEMBL509631 0.69 ADORA2A (0.37) LMNAALDH1A1HSD17B10GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022107-A1 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2012-01-26 US disclosed
US-20120022107-A1 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2012-01-26 US disclosed
US-20120022107-A1 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022107-A1 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS PIR, TLR5, ALPI LMNA 3704/4885SLC34A1 903/4885ALDH1A1 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.